BRIEF-Edwards Reports Superior TAVR Results Compared To Clinical Surveillance In At-Risk Feature

Nov 2 (Reuters) – Edwards Lifesciences Corporation : * PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES * EDWARDS

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)